BioMedNewsBreaks

WednesdayOct 01, 2025 9:00 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the closing of its $7.5 million public offering of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with proceeds intended to fund R&D, commercialization, working capital, and general corporate purposes; the financing, which included participation from existing and institutional healthcare investors, also amends prior warrants to a $1.35 exercise price and extends the company’s cash runway through the end of 2026. To view the full press release, visit https://ibn.fm/7omvV About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing…

Continue Reading

TuesdaySep 30, 2025 11:15 am

BioMedNewsBreaks — Predictive Oncology Inc. (NASDAQ: POAI) Prices $344.4 Million in PIPEs to Launch Digital Asset Treasury Strategy

  Predictive Oncology (NASDAQ: POAI) announced the pricing of two concurrent private placement transactions totaling approximately $344.4 million to support its new digital asset treasury strategy centered on ATH, the native token of the Aethir ecosystem; the deal includes a $51.7 million cash PIPE and a $292.7 million crypto PIPE involving pre-funded warrants, with proceeds earmarked for ATH acquisition, working capital, and general corporate purposes. To view the full press release, visit https://ibn.fm/8wFGz About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and…

Continue Reading

TuesdaySep 30, 2025 9:20 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell lymphoma, an 18-week study enrolling about 80 patients with top-line results expected in the second half of 2026, as the company strengthens European engagement ahead of potential commercialization. To view the full press release, visit https://ibn.fm/Xjq13 About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business…

Continue Reading

MondaySep 29, 2025 10:10 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has re-filed its Abbreviated New Drug Application with the U.S. FDA for KETAFREE(TM), a preservative-free IV ketamine formulation, covering all existing approved indications, following FDA approval of its Suitability Petition. Targeting a ketamine market estimated at $750 million annually in the U.S. and projected to reach $3.35 billion globally by 2034, NRx is seeking priority review amid an ongoing drug shortage, citing its patented formulation manufactured with Nephron Pharmaceuticals in South Carolina as a safer alternative free of benzethonium chloride, a preservative linked to neurotoxicity. To view the full press release, visit https://ibn.fm/O5lcF About…

Continue Reading

FridaySep 26, 2025 2:09 pm

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) ECG System Offers Real-Time Cardiac Insights

HeartBeam (NASDAQ: BEAT) is positioned amid limitations of traditional 12-lead electrocardiogram (“ECG”) systems, often including cumbersome setups and restricted accessibility. The company “is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately,” reads a recent article. “The HeartBeam System’s design emphasizes user friendliness and portability. The device is the…

Continue Reading

ThursdaySep 25, 2025 12:53 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Aligns With Industry Call to Fix “Broken” Biotech Model 

Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical-stage biopharmaceutical company leveraging its RADR AI platform to transform oncology drug development, was highlighted in a Dallas Innovates article covering the 2025 BioNTX iC3 Summit, where biotech leaders declared the traditional model “broken.” CEO Panna Sharma, serving as moderator and panelist, was quoted in the piece: “The process of actually making drugs is still largely manual. We have the technology to change that, but the industry hasn’t adopted it fast enough.” The article emphasized Sharma’s view that AI-driven platforms like RADR can streamline discovery, accelerate clinical timelines, and reduce costs, directly addressing the…

Continue Reading

ThursdaySep 25, 2025 9:33 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025 

Clene (NASDAQ: CLNN) announced presentation of combined REPAIR-MS trial results at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, showing CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marker of energetic capacity, across relapsing and non-active progressive MS patients. Treatment also produced significant changes in brain NAD+ and NADH fractions, with correlations between baseline brain energy metabolism and disability, cognition, and motor function. CNM-Au8 was safe and well tolerated, reinforcing its potential to slow disease progression by addressing bioenergetic failure in MS. To view the full press release, visit https://ibn.fm/uuEAj About Clene Inc.…

Continue Reading

ThursdaySep 25, 2025 9:30 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at MicroCap Rodeo Conference

Nutriband (NASDAQ: NTRB) announced it will participate in the MicroCap Rodeo Conference in New York City on Sept. 25, 2025. Company Chairman Serguei Melnik will present at 10 a.m., discussing operational highlights, growth initiatives, and the strategic direction for its AVERSA platform technology. The presentation will be webcast live, with registration available for interested parties. To view the full press release, visit https://ibn.fm/7JiVo About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated…

Continue Reading

ThursdaySep 25, 2025 9:10 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights AI Role in Breast Imaging With New Feature Article

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced the publication of a feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built for What Comes Next.” The piece underscores the limitations of legacy systems and details how the Company’s flagship IzoView Breast CT Imaging System was purpose-built for AI-driven imaging. Key points include global validation of AI’s role in improving cancer detection, IzoView’s proprietary 3D hardware and 10-second compression-free scans, and its positioning as a scalable, protected platform with a $500,000 target price designed to set a new standard in breast cancer screening. To view the…

Continue Reading

WednesdaySep 24, 2025 3:50 pm

BioMedNewsBreaks — Solving the Value-Based Care Puzzle: Adageis Brings Clarity with AI

Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. “By focusing on simplicity, contract visibility, and measurable financial outcomes, the firm aims to address one of the most pressing challenges in U.S. healthcare: how to reward high-quality care with appropriate compensation,” reads a recent article. “Adageis’ combination of AI, contract visibility, and financial monitoring places it at the intersection of healthcare technology and financial analytics. The company’s strategy, emphasizing simplicity, visibility, and measurable financial gain, is designed to…

Continue Reading